Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Key facts

Sponsor

City of Hope Medical Center

Principal Investigator

Matthew Mei, M.D

City of Hope Medical Center

Intervention

Tazemetostat(drug)

Eligibility

18 years · All sexes

Timeline

2023 – 2024

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07128641
  Odronextamab in Low Tumor Volume Advanced FL
  Gottfried von Keudell, MD PhD
• RECRUITINGNANCT07126678
  Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGEARLY PHASE1NCT06976437
  A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
  YANRU WANG
• RECRUITINGNCT06794268
  A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• RECRUITINGPHASE1NCT07093073
  Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
  Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
• RECRUITINGPHASE2NCT06959732
  Zanubrutinib Combined With G-CVP in Previously Untreated FL
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGEARLY PHASE1NCT06662227
  Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
  Wondercel Biotech (ShenZhen)
• RECRUITINGPHASE3NCT06549595
  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
  AstraZeneca

See all trials for Follicular lymphoma →